Lipid lowering in diabetes mellitus

Current Opinion in Lipidology

Volumn 19, Issue 6, 2008, Pages 579-584

  Betteridge, D John ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes mellitus; Dyslipidaemia; HDL raising; LDL lowering; Statins

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SODIUM BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; HUMANS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 56549091667     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328314b6b4     Document Type: Review

References (32)

1. Ryden L, Standl E, Bartnik M, et al. The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology and of the European Association for the Study of Diabetes. Guidelines on diabetes, prediabetes and cardiovascular diseases. Eur Heart J 2007; 9 (supplement C): C3-C74. Important document for vascular physicians, cardiologists and diabetologists reviewing CVD in diabetes and per-diabetes, its pathophysiology, identification, prevention and treatment.
2. Cubbon RM, Wheatcroft SB, Grant PJ, et al., on behalf of EMMACE (Evaluation of Methods and Management of Acute Coronary Events) Investigators). Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995-2003. Eur Heart J 2007; 28:540-545. Information from this important database of MI survivors provides the rather depressing information that modern post-MI care has not translated into improved long-term outcomes in diabetes.
3. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371:1800-1809. A very helpful review of the potential mechanisms of CVD risk in patients with type 2 diabetes including dyslipidaemia beyond LDL-cholesterol.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361:2005-2016.
5. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
6. Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
7. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below recommended levels in patients with diabetes and coronary heart disease: the Treating to New Targets (TNT) Study. Diabetes Care 2006; 29:1220-1226.
8. Shepherd J, Kastelein JJP, Bittner V, et al. Intensive lipid-lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. JACC 2008; 51:1448-1454. A new analysis from TNT indicating the increased risk of CVD in those with chronic kidney disease and the benefit and safety of intensive therapy with atorvastatin 80 mg/day.
9. Grundy SM, Cleeman JI, Merz CNB, et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227-239.
10. Colhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the CARDS investigators. Primary prevention of cardiovascular disease in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomized placebo-controlled trial. Lancet 2004; 364:685-696.
11. Colhoun HM, Betteridge DJ, Durrington PN, et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005; 48:2482-2485.
12. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29:2378-2384.
13. Hitman GA, Colhoun H, Newman C, et al., on behalf of the CARDS investigators. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetic Med 2007; 24:1313-1321. An expanded analysis of the determinants of stroke in the CARDS study. Independent risk factors were poor glycaemic control (HbA1c> 10%), albuminuria and age. Female gender and atorvastatin therapy were associated with decreased risk of stroke. No association between baseline lipids and stroke were observed.
14. Garg A. Statins for all: not so soon. Lancet 2004; 364:641-642.
15. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of satins: a meta-analysis. Lancet 2008; 371:117-125. A very important analysis of outcomes in a large sub-group of diabetic patients included in the statin randomised trials of primary and secondary prevention showing convincing evidence of evidence of benefit regardless of diabetes type, other risk factors and baseline lipid and lipoprotein concentrations.
16. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781-1790. An authorative review of the safety of statins based on RCTS that provides reassurance on the long-term safety of this important class of drugs.
17. Barter P, Gotto AM, LaRosa JC, et al., for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007; 357:1301-1310. An important analysis indicating that HDL concentrations remain predictive of CVD events even in those patients in the TNT trial who achieved an LDL-cholesterol less than 70mg/dl.
18. Brown BG, Stukovsky KH, Zhao X-Q. Simultaneous low density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006; 17:631-636.
19. Nicholls SJ, Tuzcu EM, Sipahi I, et al. High density lipoprotein cholesterol and regression of coronary atherosclerosis. JAMA 2007; 297:499-508. An interesting analysis of the impact of changes in HDL-cholesterol on atheroma progression and regression.
20. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-1515.
21. Barter PJ, Caulfield M, Eriksson M, et al., for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. The first trial of an effective agent (a CETP inhibitor) to increase HDL-cholesterol. The trial was terminated early because of increased mortality in the treated group. The agent, torcetrapib had off target effects on the adrenal but increasing HDL through this mechanism cannot be completely ruled out as contributing to the adverse outcome.
22. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 2007; 356:1364-1366. An authorative review of the ILLUMINATE trial and the potential of CETP inhibitors to reduce CVD events.
23. Van der Steeg WA, Holme I, Boekholdt M, et al. High-density lipoprotein cholesterol, high density lipoprotein particle size and apolipoprotein A-1: significance for cardiovascular risk. JACC 2008; 51:634-642. An interesting analysis from an RCT and a prospective population study pointing to the relationship of the possible adverse effects of large HDL particles.
24. Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005; 48:2477-2481.
25. Goldberg RB, Kendall DM, Deeg MA, et al., for the GLAI Study investigators. A comparison of lipid and glycaemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidaemia. Diabetes Care 2005; 28:1547-1554.
26. Dormandy JA, Charbonnel B, Eckland DJA, et al., on behalf of the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366:1279-1288.
27. Mazzone T, Meyer PM, Feinsein SB, et al. Effect of pioglitazone compared with glimpiride on carotid intima-medial thickness in type 2 diabetes; a randomized trial. JAMA 2006; 296:2572-2581.
28. Nissen SE, Nicholls SJ, Wolski K, et al., for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE randomized controlled trial. JAMA 2008; 299:1561-1573. Very important study showing for the first time that an oral hypoglycaemic drug, pioglitazone can halt progression of atheroma volume as determined by IVUS in diabetic patients already receiving evidence-based preventive medications.
29. Davidson M, Meyer PM, Haffner S, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-medicted reduction of carotid intimamedia thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117:2123-2130. In this analysis of the CHICAGO trial the impact of pioglitazone in delaying progression of IMT is related to its favourable effects in increasing HDL-cholesterol.
30. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005; 65:2719-2740.
31. Shepherd J, Betteridge DJ, Van Gaal L, on behalf of a European Consensus Panel. Nicotinic acid in the management of dyslipidaemia with diabetes and metabolic syndrome: apposition paper developed by a European Consensus Pane. Curr Med Res Opin 2005; 21:665-682.
32. Paolini JF, Mithchel YB, Reyes R, et al. Effects of liropiprant on nicotinic acid-induced flushing in patients with dyslipidaemia. Am J Cardiol 2008; 101:625-630.